Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing oral investigational therapies for rare bradykinin-mediated diseases, particularly hereditary angioedema. Its candidates are small-molecule bradykinin B2-receptor antagonists designed to target a clinically validated pathway. The company aims to address significant unmet needs by expanding treatment options, with orally administered alternatives intended to help prevent and treat attacks and improve convenience for patients living with these conditions.